$AVM Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in AMAG PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in AMAG PHARMACEUTICALS, INC.. Get notifications about new insider transactions in AMAG PHARMACEUTICALS, INC. for free.
Page: < prev 1 2 3 4 5 6 7 8 ... 11 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 26 2015 | AVM | AMAG PHARMACEUTICA ... | PEREZ ROBERT J | Director | Option Exercise | A | 66.18 | 3,575 | 236,594 | 3,575 | |
| May 26 2015 | AVM | AMAG PHARMACEUTICA ... | PEREZ ROBERT J | Director | Grant | A | 0.00 | 1,322 | 0 | 8,222 | 6.9 K to 8.2 K (+19.16 %) |
| May 26 2015 | AVM | AMAG PHARMACEUTICA ... | SULAT JAMES R | Director | Option Exercise | A | 66.18 | 3,575 | 236,594 | 3,575 | |
| May 26 2015 | AVM | AMAG PHARMACEUTICA ... | SULAT JAMES R | Director | Grant | A | 0.00 | 1,322 | 0 | 3,814 | 2.5 K to 3.8 K (+53.05 %) |
| May 26 2015 | AVM | AMAG PHARMACEUTICA ... | Deptula Barbara | Director | Option Exercise | A | 66.18 | 3,575 | 236,594 | 3,575 | |
| May 26 2015 | AVM | AMAG PHARMACEUTICA ... | Deptula Barbara | Director | Grant | A | 0.00 | 1,322 | 0 | 5,347 | 4 K to 5.3 K (+32.84 %) |
| May 26 2015 | AVM | AMAG PHARMACEUTICA ... | Fallon John A. | Director | Option Exercise | A | 66.18 | 3,575 | 236,594 | 3,575 | |
| May 26 2015 | AVM | AMAG PHARMACEUTICA ... | Fallon John A. | Director | Grant | A | 0.00 | 1,322 | 0 | 2,856 | 1.5 K to 2.9 K (+86.18 %) |
| May 26 2015 | AVM | AMAG PHARMACEUTICA ... | SANTINI GINO | Director | Option Exercise | A | 66.18 | 3,575 | 236,594 | 3,575 | |
| May 26 2015 | AVM | AMAG PHARMACEUTICA ... | SANTINI GINO | Director | Grant | A | 0.00 | 1,322 | 0 | 10,197 | 8.9 K to 10.2 K (+14.90 %) |
| May 26 2015 | AVM | AMAG PHARMACEUTICA ... | Russell Lesley | Director | Option Exercise | A | 66.18 | 3,575 | 236,594 | 3,575 | |
| May 26 2015 | AVM | AMAG PHARMACEUTICA ... | Russell Lesley | Director | Grant | A | 0.00 | 1,322 | 0 | 12,022 | 10.7 K to 12 K (+12.36 %) |
| May 26 2015 | AVM | AMAG PHARMACEUTICA ... | SCOON DAVEY | Director | Option Exercise | A | 66.18 | 3,575 | 236,594 | 3,575 | |
| May 26 2015 | AVM | AMAG PHARMACEUTICA ... | SCOON DAVEY | Director | Grant | A | 0.00 | 1,322 | 0 | 12,622 | 11.3 K to 12.6 K (+11.70 %) |
| Mar 05 2015 | AVM | AMAG PHARMACEUTICA ... | Jordan Edward P. | SVP, Sales and Mark ... | Payment of Exercise | F | 49.70 | 1,287 | 63,964 | 39,213 | 40.5 K to 39.2 K (-3.18 %) |
| Mar 05 2015 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President and CEO | Payment of Exercise | F | 49.70 | 2,474 | 122,958 | 226,974 | 229.4 K to 227 K (-1.08 %) |
| Mar 05 2015 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | EVP, Chief Operatin ... | Payment of Exercise | F | 49.70 | 4,279 | 212,666 | 129,309 | 133.6 K to 129.3 K (-3.20 %) |
| Mar 05 2015 | AVM | AMAG PHARMACEUTICA ... | Townsend Scott B | SVP, General Counse ... | Payment of Exercise | F | 49.70 | 831 | 41,301 | 56,851 | 57.7 K to 56.9 K (-1.44 %) |
| Mar 05 2015 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | SVP, Chief Accounti ... | Payment of Exercise | F | 49.70 | 533 | 26,490 | 53,304 | 53.8 K to 53.3 K (-0.99 %) |
| Feb 27 2015 | AVM | AMAG PHARMACEUTICA ... | Townsend Scott B | SVP, General Counse ... | Option Exercise | A | 49.46 | 10,000 | 494,600 | 10,000 | |
| Feb 27 2015 | AVM | AMAG PHARMACEUTICA ... | Townsend Scott B | SVP, General Counse ... | Grant | A | 0.00 | 5,000 | 0 | 57,682 | 52.7 K to 57.7 K (+9.49 %) |
| Feb 27 2015 | AVM | AMAG PHARMACEUTICA ... | Wilson Kenneth H | SVP, Sales and Mark ... | Option Exercise | A | 49.46 | 12,000 | 593,520 | 12,000 | |
| Feb 27 2015 | AVM | AMAG PHARMACEUTICA ... | Wilson Kenneth H | SVP, Sales and Mark ... | Grant | A | 0.00 | 5,000 | 0 | 30,388 | 25.4 K to 30.4 K (+19.69 %) |
| Feb 27 2015 | AVM | AMAG PHARMACEUTICA ... | Jordan Edward P. | SVP, Sales and Mark ... | Option Exercise | A | 49.46 | 10,000 | 494,600 | 10,000 | |
| Feb 27 2015 | AVM | AMAG PHARMACEUTICA ... | Jordan Edward P. | SVP, Sales and Mark ... | Grant | A | 0.00 | 5,000 | 0 | 40,500 | 35.5 K to 40.5 K (+14.08 %) |
| Feb 27 2015 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | SVP, Chief Accounti ... | Option Exercise | A | 49.46 | 10,000 | 494,600 | 10,000 | |
| Feb 27 2015 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | SVP, Chief Accounti ... | Grant | A | 0.00 | 5,000 | 0 | 53,837 | 48.8 K to 53.8 K (+10.24 %) |
| Feb 27 2015 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President and CEO | Option Exercise | A | 49.46 | 60,000 | 2,967,600 | 60,000 | |
| Feb 27 2015 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President and CEO | Grant | A | 0.00 | 30,000 | 0 | 229,448 | 199.4 K to 229.4 K (+15.04 %) |
| Feb 27 2015 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | EVP, Chief Operatin ... | Option Exercise | A | 49.46 | 25,000 | 1,236,500 | 25,000 | |
| Feb 27 2015 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | EVP, Chief Operatin ... | Grant | A | 0.00 | 12,500 | 0 | 133,588 | 121.1 K to 133.6 K (+10.32 %) |
| Jan 09 2015 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | S | 43.48 | 17,493 | 760,596 | 2,546,592 | 2.6 M to 2.5 M (-0.68 %) |
| Jan 09 2015 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | S | 46.00 | 25,169 | 1,157,774 | 2,564,085 | 2.6 M to 2.6 M (-0.97 %) |
| Jan 09 2015 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | S | 46.25 | 10,000 | 462,500 | 2,589,254 | 2.6 M to 2.6 M (-0.38 %) |
| Jan 09 2015 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | S | 45.90 | 55,000 | 2,524,500 | 2,599,254 | 2.7 M to 2.6 M (-2.07 %) |
| Jan 09 2015 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | S | 46.11 | 52,338 | 2,413,305 | 2,654,254 | 2.7 M to 2.7 M (-1.93 %) |
| Jan 09 2015 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | S | 46.60 | 1,090,000 | 50,794,000 | 2,706,592 | 3.8 M to 2.7 M (-28.71 %) |
| Dec 18 2014 | AVM | AMAG PHARMACEUTICA ... | Townsend Scott B | SVP, General Counse ... | Payment of Exercise | F | 40.49 | 1,789 | 72,437 | 52,682 | 54.5 K to 52.7 K (-3.28 %) |
| Dec 18 2014 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | EVP, Chief Operatin ... | Payment of Exercise | F | 40.49 | 7,046 | 285,293 | 121,088 | 128.1 K to 121.1 K (-5.50 %) |
| Dec 18 2014 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | SVP, Chief Accounti ... | Payment of Exercise | F | 40.49 | 859 | 34,781 | 48,837 | 49.7 K to 48.8 K (-1.73 %) |
| Dec 18 2014 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President and CEO | Payment of Exercise | F | 40.49 | 9,890 | 400,446 | 199,448 | 209.3 K to 199.4 K (-4.72 %) |
| Dec 04 2014 | AVM | AMAG PHARMACEUTICA ... | Wilson Kenneth H | SVP, Sales and Mark ... | Option Exercise | A | 39.00 | 30,000 | 1,170,000 | 30,000 | |
| Dec 04 2014 | AVM | AMAG PHARMACEUTICA ... | Wilson Kenneth H | SVP, Sales and Mark ... | Grant | A | 0.00 | 20,000 | 0 | 25,388 | 5.4 K to 25.4 K (+371.20 %) |
| Sep 08 2014 | AVM | AMAG PHARMACEUTICA ... | Fallon John A. | Director | Option Exercise | A | 23.49 | 2,534 | 59,524 | 2,534 | |
| Sep 08 2014 | AVM | AMAG PHARMACEUTICA ... | Fallon John A. | Director | Option Exercise | A | 23.49 | 6,000 | 140,940 | 6,000 | |
| Sep 08 2014 | AVM | AMAG PHARMACEUTICA ... | Fallon John A. | Director | Grant | A | 0.00 | 1,534 | 0 | 1,534 | 0 to 1.5 K |
| Aug 21 2014 | AVM | AMAG PHARMACEUTICA ... | PEREZ ROBERT J | Director | Gift | G | 0.00 | 1,900 | 0 | 6,900 | 5 K to 6.9 K (+38.00 %) |
| Aug 21 2014 | AVM | AMAG PHARMACEUTICA ... | Jordan Edward P. | SVP, Sales and Mark ... | Grant | A | 0.00 | 15,000 | 0 | 35,500 | 20.5 K to 35.5 K (+73.17 %) |
| Aug 21 2014 | AVM | AMAG PHARMACEUTICA ... | Jordan Edward P. | SVP, Sales and Mark ... | Grant | A | 0.00 | 5,000 | 0 | 20,500 | 15.5 K to 20.5 K (+32.26 %) |
| Aug 21 2014 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President and CEO | Grant | A | 0.00 | 30,000 | 0 | 209,338 | 179.3 K to 209.3 K (+16.73 %) |
| Aug 21 2014 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President and CEO | Grant | A | 0.00 | 10,000 | 0 | 179,338 | 169.3 K to 179.3 K (+5.91 %) |
| Aug 21 2014 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | SVP, Chief Accounti ... | Grant | A | 0.00 | 15,000 | 0 | 49,696 | 34.7 K to 49.7 K (+43.23 %) |
| Aug 21 2014 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | SVP, Chief Accounti ... | Grant | A | 0.00 | 5,000 | 0 | 34,696 | 29.7 K to 34.7 K (+16.84 %) |
| Aug 21 2014 | AVM | AMAG PHARMACEUTICA ... | Townsend Scott B | SVP, General Counse ... | Grant | A | 0.00 | 15,000 | 0 | 54,471 | 39.5 K to 54.5 K (+38.00 %) |
| Aug 21 2014 | AVM | AMAG PHARMACEUTICA ... | Townsend Scott B | SVP, General Counse ... | Grant | A | 0.00 | 5,000 | 0 | 39,471 | 34.5 K to 39.5 K (+14.50 %) |
| Aug 21 2014 | AVM | AMAG PHARMACEUTICA ... | Caffe Steven | SVP, Ch. Dev. and R ... | Grant | A | 0.00 | 15,000 | 0 | 59,400 | 44.4 K to 59.4 K (+33.78 %) |
| Aug 21 2014 | AVM | AMAG PHARMACEUTICA ... | Caffe Steven | SVP, Ch. Dev. and R ... | Grant | A | 0.00 | 5,000 | 0 | 44,400 | 39.4 K to 44.4 K (+12.69 %) |
| Aug 21 2014 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | EVP, Chief Operatin ... | Grant | A | 0.00 | 30,000 | 0 | 128,134 | 98.1 K to 128.1 K (+30.57 %) |
| Aug 21 2014 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | EVP, Chief Operatin ... | Grant | A | 0.00 | 10,000 | 0 | 98,134 | 88.1 K to 98.1 K (+11.35 %) |
| Jun 11 2014 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | SVP, Chief Accounti ... | Option Exercise | A | 17.86 | 30,000 | 535,800 | 30,000 | |
| Jun 11 2014 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | SVP, Chief Accounti ... | Grant | A | 0.00 | 15,000 | 0 | 29,696 | 14.7 K to 29.7 K (+102.07 %) |
| May 27 2014 | AVM | AMAG PHARMACEUTICA ... | SULAT JAMES R | Director | Option Exercise | A | 17.81 | 3,800 | 67,678 | 3,800 | |
| May 27 2014 | AVM | AMAG PHARMACEUTICA ... | SULAT JAMES R | Director | Grant | A | 0.00 | 2,300 | 0 | 2,492 | 192 to 2.5 K (+1,197.92 %) |
| May 27 2014 | AVM | AMAG PHARMACEUTICA ... | SCOON DAVEY | Director | Option Exercise | A | 17.81 | 3,800 | 67,678 | 3,800 | |
| May 27 2014 | AVM | AMAG PHARMACEUTICA ... | SCOON DAVEY | Director | Grant | A | 0.00 | 2,300 | 0 | 11,300 | 9 K to 11.3 K (+25.56 %) |
| May 27 2014 | AVM | AMAG PHARMACEUTICA ... | Deptula Barbara | Director | Option Exercise | A | 17.81 | 3,800 | 67,678 | 3,800 | |
| May 27 2014 | AVM | AMAG PHARMACEUTICA ... | Deptula Barbara | Director | Grant | A | 0.00 | 2,300 | 0 | 4,025 | 1.7 K to 4 K (+133.33 %) |
| May 27 2014 | AVM | AMAG PHARMACEUTICA ... | SANTINI GINO | Director | Option Exercise | A | 17.81 | 7,600 | 135,356 | 7,600 | |
| May 27 2014 | AVM | AMAG PHARMACEUTICA ... | SANTINI GINO | Director | Grant | A | 0.00 | 3,800 | 0 | 8,875 | 5.1 K to 8.9 K (+74.88 %) |
| May 27 2014 | AVM | AMAG PHARMACEUTICA ... | PEREZ ROBERT J | Director | Option Exercise | A | 17.81 | 3,800 | 67,678 | 3,800 | |
| May 27 2014 | AVM | AMAG PHARMACEUTICA ... | PEREZ ROBERT J | Director | Grant | A | 0.00 | 2,300 | 0 | 8,800 | 6.5 K to 8.8 K (+35.38 %) |
| May 27 2014 | AVM | AMAG PHARMACEUTICA ... | Russell Lesley | Director | Option Exercise | A | 17.81 | 3,800 | 67,678 | 3,800 | |
| May 27 2014 | AVM | AMAG PHARMACEUTICA ... | Russell Lesley | Director | Grant | A | 0.00 | 2,300 | 0 | 10,700 | 8.4 K to 10.7 K (+27.38 %) |
| Apr 16 2014 | AVM | AMAG PHARMACEUTICA ... | SULAT JAMES R | Director | Option Exercise | A | 17.26 | 317 | 5,471 | 317 | |
| Apr 16 2014 | AVM | AMAG PHARMACEUTICA ... | SULAT JAMES R | Director | Option Exercise | A | 17.26 | 6,000 | 103,560 | 6,000 | |
| Apr 16 2014 | AVM | AMAG PHARMACEUTICA ... | SULAT JAMES R | Director | Grant | A | 0.00 | 192 | 0 | 192 | 0 to 192 |
| Apr 16 2014 | AVM | AMAG PHARMACEUTICA ... | PEREZ ROBERT J | Director | Gift | G | 0.00 | 2,500 | 0 | 6,500 | 9 K to 6.5 K (-27.78 %) |
| Feb 28 2014 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President and CEO | Option Exercise | A | 21.13 | 93,800 | 1,981,994 | 93,800 | |
| Feb 28 2014 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President and CEO | Grant | A | 0.00 | 15,600 | 0 | 169,338 | 153.7 K to 169.3 K (+10.15 %) |
| Feb 28 2014 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | VP, Chief Accountin ... | Option Exercise | A | 21.13 | 18,800 | 397,244 | 18,800 | |
| Feb 28 2014 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | VP, Chief Accountin ... | Grant | A | 0.00 | 3,100 | 0 | 14,696 | 11.6 K to 14.7 K (+26.73 %) |
| Feb 28 2014 | AVM | AMAG PHARMACEUTICA ... | Townsend Scott B | SVP, General Counse ... | Option Exercise | A | 21.13 | 30,000 | 633,900 | 30,000 | |
| Feb 28 2014 | AVM | AMAG PHARMACEUTICA ... | Townsend Scott B | SVP, General Counse ... | Grant | A | 0.00 | 5,000 | 0 | 34,471 | 29.5 K to 34.5 K (+16.97 %) |
| Feb 28 2014 | AVM | AMAG PHARMACEUTICA ... | Caffe Steven | SVP, Ch. Dev. and R ... | Option Exercise | A | 21.13 | 26,300 | 555,719 | 26,300 | |
| Feb 28 2014 | AVM | AMAG PHARMACEUTICA ... | Caffe Steven | SVP, Ch. Dev. and R ... | Grant | A | 0.00 | 4,400 | 0 | 39,400 | 35 K to 39.4 K (+12.57 %) |
| Feb 28 2014 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | EVP, Chief Operatin ... | Option Exercise | A | 21.13 | 33,800 | 714,194 | 33,800 | |
| Feb 28 2014 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | EVP, Chief Operatin ... | Grant | A | 0.00 | 5,600 | 0 | 88,134 | 82.5 K to 88.1 K (+6.79 %) |
| Feb 28 2014 | AVM | AMAG PHARMACEUTICA ... | White Christopher G | Chief Business Offi ... | Option Exercise | A | 21.13 | 26,300 | 555,719 | 26,300 | |
| Feb 28 2014 | AVM | AMAG PHARMACEUTICA ... | White Christopher G | Chief Business Offi ... | Grant | A | 0.00 | 4,400 | 0 | 28,400 | 24 K to 28.4 K (+18.33 %) |
| Feb 26 2014 | AVM | AMAG PHARMACEUTICA ... | White Christopher G | Chief Business Offi ... | Sell | S | 21.58 | 400 | 8,632 | 24,000 | 24.4 K to 24 K (-1.64 %) |
| Feb 26 2014 | AVM | AMAG PHARMACEUTICA ... | White Christopher G | Chief Business Offi ... | Sell | S | 21.71 | 434 | 9,422 | 24,400 | 24.8 K to 24.4 K (-1.75 %) |
| Feb 25 2014 | AVM | AMAG PHARMACEUTICA ... | Edward P. Jordan | SVP, Sales and Mark ... | Option Exercise | A | 21.76 | 30,000 | 652,800 | 30,000 | |
| Feb 25 2014 | AVM | AMAG PHARMACEUTICA ... | Edward P. Jordan | SVP, Sales and Mark ... | Grant | A | 0.00 | 15,000 | 0 | 15,500 | 500 to 15.5 K (+3,000.00 %) |
| Jan 09 2014 | AVM | AMAG PHARMACEUTICA ... | White Christopher G | Chief Business Offi ... | Sell | S | 22.41 | 200 | 4,482 | 24,834 | 25 K to 24.8 K (-0.80 %) |
| Jan 09 2014 | AVM | AMAG PHARMACEUTICA ... | White Christopher G | Chief Business Offi ... | Sell | S | 21.40 | 100 | 2,140 | 25,034 | 25.1 K to 25 K (-0.40 %) |
| Jan 09 2014 | AVM | AMAG PHARMACEUTICA ... | White Christopher G | Chief Business Offi ... | Sell | S | 20.61 | 1,700 | 35,037 | 25,134 | 26.8 K to 25.1 K (-6.34 %) |
| Jan 09 2014 | AVM | AMAG PHARMACEUTICA ... | White Christopher G | Chief Business Offi ... | Sell | S | 23.91 | 2,000 | 47,820 | 26,834 | 28.8 K to 26.8 K (-6.94 %) |
| Jan 07 2014 | AVM | AMAG PHARMACEUTICA ... | White Christopher G | Chief Business Offi ... | Sell | S | 24.10 | 2,500 | 60,250 | 28,834 | 31.3 K to 28.8 K (-7.98 %) |
| Jan 07 2014 | AVM | AMAG PHARMACEUTICA ... | White Christopher G | Chief Business Offi ... | Sell | S | 23.69 | 2,500 | 59,225 | 31,334 | 33.8 K to 31.3 K (-7.39 %) |
| Dec 17 2013 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | EVP, Chief Operatin ... | Payment of Exercise | F | 23.23 | 3,266 | 75,869 | 82,534 | 85.8 K to 82.5 K (-3.81 %) |
| Dec 17 2013 | AVM | AMAG PHARMACEUTICA ... | Townsend Scott B | SVP, General Counse ... | Payment of Exercise | F | 23.23 | 1,429 | 33,196 | 29,471 | 30.9 K to 29.5 K (-4.62 %) |
| Dec 17 2013 | AVM | AMAG PHARMACEUTICA ... | Holmes Scott A | VP, Chief Accountin ... | Payment of Exercise | F | 23.23 | 654 | 15,192 | 11,596 | 12.3 K to 11.6 K (-5.34 %) |
| Sep 26 2013 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | D | 26.80 | 10,000 | 268,000 | 3,796,592 | 3.8 M to 3.8 M (-0.26 %) |
| Sep 09 2013 | AVM | AMAG PHARMACEUTICA ... | Deptula Barbara | Director | Option Exercise | A | 24.82 | 2,850 | 70,737 | 2,850 | |
| Sep 09 2013 | AVM | AMAG PHARMACEUTICA ... | Deptula Barbara | Director | Option Exercise | A | 24.82 | 6,000 | 148,920 | 6,000 | |
| Sep 09 2013 | AVM | AMAG PHARMACEUTICA ... | Deptula Barbara | Director | Grant | A | 0.00 | 1,725 | 0 | 1,725 | 0 to 1.7 K |
| Sep 06 2013 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | D | 24.97 | 10,000 | 249,700 | 3,806,592 | 3.8 M to 3.8 M (-0.26 %) |
| Sep 06 2013 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | D | 24.98 | 4,700 | 117,406 | 3,816,592 | 3.8 M to 3.8 M (-0.12 %) |
| Sep 06 2013 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | D | 24.90 | 3,800 | 94,620 | 3,821,292 | 3.8 M to 3.8 M (-0.10 %) |
| Sep 03 2013 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | D | 24.50 | 10,000 | 245,000 | 3,825,092 | 3.8 M to 3.8 M (-0.26 %) |
| Sep 03 2013 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | D | 23.70 | 18,600 | 440,820 | 3,835,092 | 3.9 M to 3.8 M (-0.48 %) |
| Sep 03 2013 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | D | 24.76 | 10,000 | 247,600 | 3,853,692 | 3.9 M to 3.9 M (-0.26 %) |
| Aug 28 2013 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | D | 25.02 | 12,000 | 300,240 | 0 | 12 K to 0 (-100.00 %) |
| Aug 28 2013 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | D | 25.00 | 3,100 | 77,500 | 3,875,692 | 3.9 M to 3.9 M (-0.08 %) |
| Aug 23 2013 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | D | 24.42 | 3,600 | 87,912 | 0 | 3.6 K to 0 (-100.00 %) |
| Aug 23 2013 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | D | 24.36 | 11,000 | 267,960 | 0 | 11 K to 0 (-100.00 %) |
| Aug 23 2013 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | D | 24.26 | 8,000 | 194,080 | 0 | 8 K to 0 (-100.00 %) |
| Aug 23 2013 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | D | 24.19 | 1,000 | 24,190 | 0 | 1,000 to 0 (-100.00 %) |
| Aug 23 2013 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | D | 23.51 | 1,400 | 32,914 | 0 | 1.4 K to 0 (-100.00 %) |
| Aug 23 2013 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | D | 23.46 | 400 | 9,384 | 3,903,792 | 3.9 M to 3.9 M (-0.01 %) |
| Aug 08 2013 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Buy | D | 23.50 | 1,100 | 25,850 | 3,904,192 | 3.9 M to 3.9 M (+0.03 %) |
| Aug 02 2013 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | D | 23.70 | 5,500 | 130,350 | 3,905,292 | 3.9 M to 3.9 M (-0.14 %) |
| Aug 02 2013 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | D | 24.12 | 1,100 | 26,532 | 3,910,792 | 3.9 M to 3.9 M (-0.03 %) |
| Aug 02 2013 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | D | 23.74 | 7,900 | 187,546 | 3,911,892 | 3.9 M to 3.9 M (-0.20 %) |
| Aug 02 2013 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | D | 23.61 | 17,038 | 402,267 | 3,919,792 | 3.9 M to 3.9 M (-0.43 %) |
| Aug 02 2013 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | D | 23.00 | 44,200 | 1,016,600 | 3,936,830 | 4 M to 3.9 M (-1.11 %) |
| Aug 02 2013 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | D | 23.07 | 9,300 | 214,551 | 3,981,030 | 4 M to 4 M (-0.23 %) |
| Aug 02 2013 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | D | 23.00 | 95,000 | 2,185,000 | 3,990,330 | 4.1 M to 4 M (-2.33 %) |
| Jun 24 2013 | AVM | AMAG PHARMACEUTICA ... | Caffe Steven | SVP, Ch. Dev. and R ... | Option Exercise | A | 20.36 | 60,000 | 1,221,600 | 60,000 | |
| Jun 24 2013 | AVM | AMAG PHARMACEUTICA ... | Caffe Steven | SVP, Ch. Dev. and R ... | Grant | A | 0.00 | 35,000 | 0 | 35,000 | 0 to 35 K |
| May 28 2013 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President and CEO | Option Exercise | M | 12.99 | 10,000 | 129,900 | 290,000 | |
| May 28 2013 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President and CEO | Buy | M | 12.99 | 10,000 | 129,900 | 153,738 | 143.7 K to 153.7 K (+6.96 %) |
| May 24 2013 | AVM | AMAG PHARMACEUTICA ... | PEREZ ROBERT J | Director | Option Exercise | A | 21.94 | 3,800 | 83,372 | 3,800 | |
| May 24 2013 | AVM | AMAG PHARMACEUTICA ... | PEREZ ROBERT J | Director | Grant | A | 0.00 | 2,300 | 0 | 9,000 | 6.7 K to 9 K (+34.33 %) |
| May 24 2013 | AVM | AMAG PHARMACEUTICA ... | NARACHI MICHAEL | Director | Option Exercise | A | 21.94 | 7,600 | 166,744 | 7,600 | |
| May 24 2013 | AVM | AMAG PHARMACEUTICA ... | NARACHI MICHAEL | Director | Grant | A | 0.00 | 3,800 | 0 | 23,900 | 20.1 K to 23.9 K (+18.91 %) |
| May 24 2013 | AVM | AMAG PHARMACEUTICA ... | Russell Lesley | Director | Option Exercise | A | 21.94 | 3,800 | 83,372 | 3,800 | |
| May 24 2013 | AVM | AMAG PHARMACEUTICA ... | Russell Lesley | Director | Grant | A | 0.00 | 2,300 | 0 | 8,400 | 6.1 K to 8.4 K (+37.70 %) |
| May 24 2013 | AVM | AMAG PHARMACEUTICA ... | SCOON DAVEY | Director | Option Exercise | A | 21.94 | 3,800 | 83,372 | 3,800 | |
| May 24 2013 | AVM | AMAG PHARMACEUTICA ... | SCOON DAVEY | Director | Grant | A | 0.00 | 2,300 | 0 | 9,000 | 6.7 K to 9 K (+34.33 %) |
| May 24 2013 | AVM | AMAG PHARMACEUTICA ... | ADAGE CAPITAL PARTNERS GP LLC | 10% Owner | Sell | D | 24.00 | 50,000 | 1,200,000 | 4,085,330 | 4.1 M to 4.1 M (-1.21 %) |
| May 24 2013 | AVM | AMAG PHARMACEUTICA ... | SANTINI GINO | Director | Option Exercise | A | 21.94 | 3,800 | 83,372 | 3,800 | |
| May 24 2013 | AVM | AMAG PHARMACEUTICA ... | SANTINI GINO | Director | Grant | A | 0.00 | 2,300 | 0 | 5,075 | 2.8 K to 5.1 K (+82.88 %) |
| May 15 2013 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President and CEO | Option Exercise | M | 0.00 | 25,000 | 0 | 75,000 | |
| May 15 2013 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President and CEO | Payment of Exercise | F | 25.03 | 8,162 | 204,295 | 68,738 | 76.9 K to 68.7 K (-10.61 %) |
| May 15 2013 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President and CEO | Buy | M | 0.00 | 25,000 | 0 | 76,900 | 51.9 K to 76.9 K (+48.17 %) |
| Mar 04 2013 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President and CEO | Option Exercise | A | 16.55 | 86,300 | 1,428,265 | 86,300 | |
| Mar 04 2013 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President and CEO | Grant | A | 0.00 | 27,500 | 0 | 51,900 | 24.4 K to 51.9 K (+112.70 %) |
| Mar 04 2013 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President and CEO | Grant | A | 0.00 | 14,400 | 0 | 24,400 | 10 K to 24.4 K (+144.00 %) |
| Mar 04 2013 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | EVP, Chief Operatin ... | Option Exercise | A | 16.55 | 37,500 | 620,625 | 37,500 |